Health Care • Biotechnology: Commercial Physical & Biological Resarch
$120.39 ▲ +3.59
(+3.07%)
MKT CAP: $23.68B • VOL: 2.84M
52W L $89 52W H $133
INCY // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $5.14B | $4.24B | $3.70B |
| YoY Revenue Growth % | +21.2% | +14.8% | — |
| Gross Profit | $4.77B | $3.93B | — |
| Gross Margin % | 92.8% | 92.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $1.51B | $61.4M | $620.5M |
| Operating Margin % | 29.5% | 1.4% | 16.8% |
| Net Income (GAAP) | $1.29B | $32.6M | $597.6M |
| EBITDA (Normalized) | $1.70B | $214.0M | $753.6M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.41B | $335.3M | $496.5M |
| Capital Expenditures (CapEx) | $231.4M | $190.9M | $166.3M |
| Free Cash Flow (FCF) | $1.18B | $144.5M | $330.2M |
| FCF Margin % | 23.0% | 3.4% | 8.9% |
| Return on Invested Capital (ROIC %) | 41.6% | 1.8% | 6.2% |
| Cash & Short-Term Equivalents | $3.10B | $1.69B | — |
| Total Debt (Short + Long Term) | $805.7M | $898.5M | $3.05B |
| Total Stockholders' Equity | $5.17B | $3.45B | $6.25B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR INCY.